Madrigal Pharmaceuticals (MDGL) Receiving Somewhat Favorable Press Coverage, Study Finds

News articles about Madrigal Pharmaceuticals (NASDAQ:MDGL) have trended somewhat positive on Friday, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Madrigal Pharmaceuticals earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.9015541274305 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Shares of Madrigal Pharmaceuticals (NASDAQ MDGL) traded up 0.83% during trading on Friday, hitting $15.75. 8,616 shares of the stock traded hands. The company has a 50-day moving average of $15.72 and a 200-day moving average of $15.69. Madrigal Pharmaceuticals has a 52 week low of $8.74 and a 52 week high of $18.24. The firm’s market cap is $196.80 million.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Thursday, August 10th. The biopharmaceutical company reported ($0.69) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.09. On average, analysts forecast that Madrigal Pharmaceuticals will post ($2.57) EPS for the current fiscal year.

Separately, ValuEngine raised shares of Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, May 19th.

TRADEMARK VIOLATION NOTICE: This article was originally posted by BNB Daily and is the property of of BNB Daily. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).

Receive News & Ratings for Madrigal Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply